-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Sees Large Decrease in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Sees Large Decrease in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 9,100 shares, a drop of 18.0% from the December 15th total of 11,100 shares. Based on an average daily volume of 28,500 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's shares are sold short.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of PBAX. Hsbc Holdings PLC lifted its position in Phoenix Biotech Acquisition by 178.7% during the 3rd quarter. Hsbc Holdings PLC now owns 729,499 shares of the company's stock valued at $7,361,000 after acquiring an additional 467,776 shares during the period. Westchester Capital Management LLC purchased a new position in Phoenix Biotech Acquisition during the 2nd quarter valued at about $4,626,000. Woodline Partners LP lifted its position in Phoenix Biotech Acquisition by 1,100.0% during the 2nd quarter. Woodline Partners LP now owns 300,000 shares of the company's stock valued at $3,006,000 after acquiring an additional 275,000 shares during the period. Wolverine Asset Management LLC lifted its position in Phoenix Biotech Acquisition by 161.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 404,576 shares of the company's stock valued at $4,053,000 after acquiring an additional 250,010 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Phoenix Biotech Acquisition during the 2nd quarter valued at about $2,404,000. 65.93% of the stock is owned by hedge funds and other institutional investors.
Get Phoenix Biotech Acquisition alerts:Phoenix Biotech Acquisition Price Performance
Shares of NASDAQ PBAX opened at $10.36 on Friday. Phoenix Biotech Acquisition has a 1 year low of $9.90 and a 1 year high of $11.76. The firm has a 50-day moving average of $10.28 and a 200 day moving average of $10.16.
About Phoenix Biotech Acquisition
(Get Rating)Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 9,100 shares, a drop of 18.0% from the December 15th total of 11,100 shares. Based on an average daily volume of 28,500 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's shares are sold short.
菲尼克斯生物技术收购公司(纳斯达克股票代码:PBAX — 获取评级)是12月份空头利率大幅下降的受益者。截至12月30日,空头利息总额为9,100股,较12月15日的11,100股下降了18.0%。根据28,500股的平均每日交易量,空头利率目前为0.3天。该公司约有0.1%的股票被卖空。
Institutional Inflows and Outflows
机构流入和流出
A number of large investors have recently bought and sold shares of PBAX. Hsbc Holdings PLC lifted its position in Phoenix Biotech Acquisition by 178.7% during the 3rd quarter. Hsbc Holdings PLC now owns 729,499 shares of the company's stock valued at $7,361,000 after acquiring an additional 467,776 shares during the period. Westchester Capital Management LLC purchased a new position in Phoenix Biotech Acquisition during the 2nd quarter valued at about $4,626,000. Woodline Partners LP lifted its position in Phoenix Biotech Acquisition by 1,100.0% during the 2nd quarter. Woodline Partners LP now owns 300,000 shares of the company's stock valued at $3,006,000 after acquiring an additional 275,000 shares during the period. Wolverine Asset Management LLC lifted its position in Phoenix Biotech Acquisition by 161.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 404,576 shares of the company's stock valued at $4,053,000 after acquiring an additional 250,010 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Phoenix Biotech Acquisition during the 2nd quarter valued at about $2,404,000. 65.93% of the stock is owned by hedge funds and other institutional investors.
许多大型投资者最近买入和卖出了PBAX的股票。汇丰控股有限公司在第三季度将其在菲尼克斯生物科技收购中的头寸提高了178.7%。汇丰控股有限公司在此期间又收购了467,776股股票后,现在拥有该公司729,499股股票,价值7,361,000美元。威彻斯特资本管理有限责任公司在第二季度收购了菲尼克斯生物技术收购的新头寸,价值约4,626,000美元。Woodline Partners LP在第二季度将其在收购菲尼克斯生物技术公司中的头寸提高了1,100.0%。Woodline Partners LP在此期间又收购了27.5万股股票后,现在拥有该公司30万股股票,价值3,006,000美元。金刚狼资产管理有限责任公司在第二季度将其在菲尼克斯生物技术收购中的头寸提高了161.7%。金刚狼资产管理有限责任公司在此期间又收购了250,010股股票后,现在拥有该公司404,576股股票,价值4,053,000美元。最后,Cubist Systematic Strategies LLC在第二季度购买了Phoenix Biotech收购的新头寸,价值约24.4万美元。该股票的65.93%由对冲基金和其他机构投资者持有。
Phoenix Biotech Acquisition Price Performance
菲尼克斯生物科技收购价格表现
Shares of NASDAQ PBAX opened at $10.36 on Friday. Phoenix Biotech Acquisition has a 1 year low of $9.90 and a 1 year high of $11.76. The firm has a 50-day moving average of $10.28 and a 200 day moving average of $10.16.
纳斯达克PBAX的股票周五开盘价为10.36美元。菲尼克斯生物科技的收购创1年低点为9.90美元,1年高点为11.76美元。该公司的50天移动平均线为10.28美元,200天移动平均线为10.16美元。
About Phoenix Biotech Acquisition
关于收购菲尼克斯生物科技
Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
菲尼克斯生物技术收购公司没有重大业务。公司打算与一家或多家企业进行合并、股份交换、资产收购、股票购买、重组或类似的业务合并。它参与识别和收购一家专注于美国和欧洲医疗保健或医疗保健相关行业的企业。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取 StockNews.com 关于收购菲尼克斯生物技术 (PBAX) 的研究报告
- MarketBeat Week 回顾 — 1/16 — 1/20
- Old Dominion 是否表明卡车运输正在刹车?
- 诺德斯特龙将对降价的恐惧带入零售业
- 埃克森美孚股票:距离买入点仅几步之遥
- 高股息收益的必和必拓认为中国将推动 “23” 的增长
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收Phoenix Biotech收购的新闻和评级——在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收有关菲尼克斯生物技术收购及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧